Meeting
2022 ASCO Annual Meeting
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
Authors
Toshio Shimizu
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
Toshio Shimizu , Kan Yonemori , Takafumi Koyama , Yuki Katsuya , Jun Sato , Noriko Fukuhara , Hisayuki Yokoyama , Hiroatsu Iida , Koji Ando , Suguru Fukuhara , Hiroshi Miyake , Yasushi Tanoue , Hirokazu Tozaki , Akio Mizutani , Daisuke Morishita , Kunihiko Takeyama , Noboru Yamamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
JapicCTI-184188
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3080)
DOI
10.1200/JCO.2022.40.16_suppl.3080
Abstract #
3080
Poster Bd #
72
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2022 ASCO Annual Meeting
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.
First Author: Jifang Gong